SPARKS, MD—(Marketwired – September 28, 2016) – Commence Bio, Inc., a biotechnology company focused on developing breakthrough immunotherapies using its proprietary STaRTâ¢ platform, announced today that Thomas Isett, CEO and Co–Founder, will present a company overview at the 2016 Cell & Gene Meeting on the Mesa [CGMOM]. Scheduled for October 5, at 2:45 PM (PDT), the presentation will highlight developments with the application of STaRT to create MSC1 and MSC2 cellular therapies for immuno–oncology and immune–mediated inflammatory diseases.
Organized by ARM and the Sanford Consortium for Regenerative Medicine, CGMOM is a three day conference featuring a two day Partnering Forum and a full–day Scientific Symposium. The Commence Bio presentation will be webcast live during the Forum, and will also be published on ARM's website shortly after the event.
About Commence Bio
Commence Bio, Inc., is a pre–clinical stage biotechnology company founded on the vision that cancer and inflammatory diseases can be optimally treated by rebooting patients' immune systems with a new class of cell therapies: MSC1& MSC2. Through the use of proprietary Stimulated Toll–like Receptor Technology [STaRTâ¢], adult, allogeneic mesenchymal stem cells [MSCs] are transformed into powerful immunomodulators that migrate to the sites of immune dysfunction and – via a multi–pronged effect – re–awaken the body's innate and adaptive immune responses. MSC1 & MSC2 have proven to be safe, potent, and efficacious in seven pre–clinical models of disease, including ovarian cancer, demyelinating diseases (i.e. multiple sclerosis and Krabbe disease), acute lung injury/ARDS, Crohn's disease, rheumatoid arthritis, and diabetic neuropathic pain. Commence Bio is the STaRT of something big in immunotherapy.